CSL-112

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameCSL-112
Drug Alias NameCSL112 (reconstituted HDL) - CSLApolipoprotein A-I - CSL BehringrHDL - CSLCSL112 apo-AICSL-112
ClassificationBiologics
Mechanisms of ActionCholesterol modulators
TargetsCholesterol
Therapy Area/IndicationsMyocardial InfarctionAcute Coronary SyndromeKidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring
Inactive CompaniesCsl Ltd
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsMyocardial InfarctionKidney Diseases

Other Information

ATC CodeN/A
Related LinksN/A